|
1.
|
Jemal A, Siegel R, Ward E, Murray T, Xu J,
Smigal C and Thun MJ: Cancer statistics, 2006. CA Cancer J Clin.
56:106–130. 2006. View Article : Google Scholar
|
|
2.
|
Woodward RM, Brown ML, Stewart ST, Cronin
KA and Cutler DM: The value of medical interventions for lung
cancer in the elderly: results from SEER-CMHSF. Cancer.
110:2511–2518. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
3.
|
Ernst A, Anantham D, Eberhardt R, Krasnik
M and Herth FJ: Diagnosis of mediastinal adenopathy-real-time
endobronchial ultrasound guided needle aspiration versus
mediastinoscopy. J Thorac Oncol. 3:577–582. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Nakashima A, Murakami Y, Uemura K, et al:
Usefulness of human telomerase reverse transcriptase in pancreatic
juice as a biomarker of pancreatic malignancy. Pancreas.
38:527–533. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Ghaneh P, Greenhalf W, Humphreys M, et al:
Adenovirus-mediated transfer of p53 and p16 (INK4a) results in
pancreatic cancer regression in vitro and in vivo. Gene Ther.
8:199–208. 2007. View Article : Google Scholar
|
|
6.
|
Soussi T: p53 antibodies in the sera of
patients with various types of cancer. Cancer Res. 60:1777–1788.
2010.PubMed/NCBI
|
|
7.
|
Looi K, Megliorino R, Shi FD, Peng XX,
Chen Y and Zhang JY: Humoral immune response to p16, a
cyclin-dependent kinase inhibitor in human malignancies. Oncol Rep.
16:1105–1110. 2006.PubMed/NCBI
|
|
8.
|
Zhang JY, Chan EK, Peng XX and Tan EM: A
novel cytoplasmic protein with RNA-binding motifs is an autoantigen
in human hepatocellular carcinoma. J Exp Med. 189:1101–1110. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Park KH, Gad E, Goodell V, et al:
Insulin-like growth factor-binding protein-2 is a target for the
immunomodulation of breast cancer. Cancer Res. 68:8400–8409. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Lin Y, Jiang T, Zhou K, et al: Plasma
IGFBP-2 levels predict clinical outcomes of patients with
high-grade gliomas. Neuro Oncol. 11:468–476. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Miraki-Moud F, Jenkins PJ, Fairclough PD,
et al: Increased levels of insulin-like growth factor binding
protein-2 in sera and tumours from patients with colonic neoplasia
with and without acromegaly. Clin Endocrinol (Oxf). 54:499–508.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Liou JM, Shun CT, Liang JT, et al: Plasma
insulin-like growth factor-binding protein-2 levels as diagnostic
and prognostic biomarker of colorectal cancer. J Clin Endocrinol
Metab. 95:1717–1725. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Shariat SF, Lamb DJ, Kattan MW, et al:
Association of preoperative plasma levels of insulin-like growth
factor I and insulin-like growth factor binding proteins-2 and -3
with prostate cancer invasion, progression, and metastasis. J Clin
Oncol. 20:833–841. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Wang H, Rosen DG, Wang H, Fuller GN, Zhang
W and Liu J: Insulin-like growth factor-binding protein 2 and 5 are
differentially regulated in ovarian cancer of different histologic
types. Mod Pathol. 19:1149–1156. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Busund LT, Richardsen E, Busund R, Ukkonen
T, Bjørnsen T, Busch C and Stalsberg H: Significant expression of
IGFBP2 in breast cancer compared with benign lesions. J Clin
Pathol. 58:361–366. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Baron-Hay S, Boyle F, Ferrier A and Scott
C: Elevated serum insulin-like growth factor binding protein-2 as a
prognostic marker in patients with ovarian cancer. Clin Cancer Res.
10:1796–1806. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Li Y, Jiang T, Zhang J, et al: Elevated
serum antibodies against insulin-like growth factor-binding
protein-2 allow detecting early-stage cancers: evidences from
glioma and colorectal carcinoma studies. Ann Oncol. 23:2415–2422.
2012. View Article : Google Scholar
|
|
18.
|
Pereira JJ, Meyer T, Docherty SE, Reid HH,
et al: Bimolecular interaction of insulin-like growth factor (IGF)
binding protein-2 with alphavbeta3 negatively modulates
IGF-I-mediated migration and tumor growth. Cancer Res. 64:977–984.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Wang GK, Hu L, Fuller GN and Zhang W: An
interaction between insulin-like growth factor-binding protein 2
(IGFBP2) and integrin alpha5 is essential for IGFBP2-induced cell
mobility. J Biol Chem. 281:14085–14091. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
Hoeflich A, Reisinger R, Lahm H, et al:
Insulin-like growth factor-binding protein 2 in tumorigenesis:
protector or promoter. Cancer Res. 61:8601–8610. 2001.PubMed/NCBI
|
|
21.
|
Lee EJ, Mircean C, Shmulevich I, et al:
Insulin-like growth factor binding protein 2 promotes ovarian
cancer cell invasion. Mol Cancer. 4:72005. View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Miyake H, Hara I, Yamanaka K, Muramaki M,
Gleave M and Eto H: Introduction of insulin-like growth factor
binding protein-2 gene into human bladder cancer cells enhances
their metastatic potential. Oncol Rep. 13:341–345. 2005.
|
|
23.
|
Schütt BS, Langkamp M, Rauschnabel U,
Ranke MB and Elmlinger MW: Integrin-mediated action of insulin-like
growth factor binding protein-2 in tumor cells. J Mol Endocrinol.
32:859–868. 2004.PubMed/NCBI
|
|
24.
|
Hoeflich A, Reisinger R, Schuett BS, et
al: Peri/nuclear localization of intact insulin-like growth factor
binding protein-2 and a distinct carboxyl-terminal IGFBP-2 fragment
in vivo. Biochem Biophys Res Commun. 324:705–710. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
25.
|
Hoeflich A, Fettscher O, Lahm H, et al:
Overexpression of insulin-like growth factor-binding protein-2
results in increased tumorigenic potential in Y-1 adrenocortical
tumor cells. Cancer Res. 60:834–838. 2000.PubMed/NCBI
|
|
26.
|
Chatterjee S, Park ES and Soloff MS:
Proliferation of DU145 prostate cancer cells is inhibited by
suppressing insulin-like growth factor binding protein-2. Int J
Urol. 11:876–884. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
27.
|
Vorwerk P, Mohnike K, Wex H, Röhl FW,
Zimmermann M, Blum WF and Mittler U: Insulin-like growth factor
binding protein-2 at diagnosis of childhood acute lymphoblastic
leukemia and the prediction of relapse risk. J Clin Endocrinol
Metab. 90:3022–3027. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
28.
|
Mehrian-Shai R, Chen CD, Shi T, et al:
Insulin growth factor-binding protein 2 is a candidate biomarker
for PTEN status and PI3K/Akt pathway activation in glioblastoma and
prostate cancer. Proc Natl Acad Sci USA. 104:5563–5568. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
29.
|
Grimberg A, Coleman CM, Shi Z, Burns TF,
MacLachlan TK, Wang W and El-Deiry WS: Insulin-like growth factor
factor binding protein-2 is a novel mediator of p53 inhibition of
insulin-like growth factor signaling. Cancer Biol Ther.
5:1408–1414. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
30.
|
Migita T, Narita T, Asaka R, et al: Role
of insulin-like growth factor binding protein 2 in lung
adenocarcinoma: IGF-independent antiapoptotic effect via caspase-3.
Am J Pathol. 176:1756–1766. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
31.
|
Lubin R, Schlichtholz B, Teillaud JL,
Garay E, Bussel A and Wild CP: p53 antibodies in patients with
various types of cancer assay, identification, and
characterization. Clin Cancer Res. 1:1463–1469. 1995.PubMed/NCBI
|
|
32.
|
Comtesse N, Zippel A, Walle S, et al:
Complex humoral immune response against a benign tumor: frequent
antibody response against specific antigens as diagnostic targets.
Proc Natl Acad Sci USA. 102:9601–9606. 2005. View Article : Google Scholar
|
